"Western New York Urology Associates is committed to providing compassionate, quality care in a prompt and friendly manner. With our world-class expertise and state-of-the-art technology, we are uniquely qualified to help patients throughout Western New York from Orchard Park, Niagara Falls, NY as well as the Southern Tier and Northern Pennsylvania understand and seek treatment for the urological conditions. Call us today for more information."

During the past decade, Western New York Urology Associates conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 3 clinical trials were completed, i.e. on average, 30% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Western New York Urology Associates" #1 sponsor was "SWOG Cancer Research Network" with 6 trials, followed by "Allergan" with 3 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "UroGen Pharma Ltd." with 2 trials sponsored and "Curbell Medical Products, Inc." with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Western New York Urology Associates" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "ClinLogix. LLC" with 1 trials as a collaborator, "Eastern Cooperative Oncology Group" with 1 trials as a collaborator and "SWOG Cancer Research Network" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Western New York Urology Associates" are "Bladder Cancer" (3 trials), "Prostatic Neoplasms" (2 trials), "Urinary Incontinence" (2 trials), "Urothelial Carcinoma" (2 trials) and "Urothelial Carcinoma Bladder" (2 trials). Many other conditions were trialed in "Western New York Urology Associates" in a lesser frequency.

Most popular intervention types in "Western New York Urology Associates" are "Drug" (13 trials), "Procedure" (3 trials), "Radiation" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "gemcitabine hydrochloride" (3 trials), "paclitaxel" (3 trials), "Apalutamide" (2 trials), "Placebo" (2 trials) and "UGN-102" (2 trials). Other intervention names were less common.

The vast majority of trials in "Western New York Urology Associates" are 8 trials for "All" genders, 6 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Western New York Urology Associates". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Western New York Urology Associates, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Western New York Urology Associates, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".